Background Second-generation antipsychotic drugs were introduced over a decade ago for the treatment of schizophrenia; however, their purported clinical effectiveness compared with first-generation antipsychotic drugs is still debated. We aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode schizophrenia.
Introduction
Second-generation antipsychotic drugs were introduced over a decade ago. They were intended to be more efficacious than were previous drugs for treatment of schizophrenia, and less likely to induce motor side-effects. However, their clinical effectiveness compared with firstgeneration antipsychotic drugs is still debated. [1] [2] [3] [4] [5] Indeed, limited conclusions can be drawn from the studies that have been undertaken so far, 6 since most used restrictive inclusion criteria, leading to over-representation of men and under-representation of patients with comorbidities, such as drug abuse. Moreover, treatment response has almost exclusively been defined by use of scales that measure the extent of psychopathology: in most studies, efficacy has been measured, according to narrowly-defined criteria, but not effectiveness, which is a combination of efficacy and tolerability. Some investigators suggest that trials showing that second-generation antipsychotic drugs are better than haloperidol used doses of haloperidol that were too high. 2 Finally, study durations have typically been less than 2 months, which is imperfect for an illness potentially lasting a lifetime. [6] [7] [8] We 7 and others 6 have suggested that studies that are not restrictive in the inclusion of patients, have long follow-up periods, and use outcome measures which are clinically meaningful, are urgently needed. The time for which patients continue to use a drug is considered a good measure of effectiveness. Even in short-term studies, fewer than 50-60% of patients continue to take their drugs before the study is complete. 9 Pragmatic (open) randomised trials, comparing second-generation drugs with older ones, will arguably provide a better indication of the true value of these drugs in clinical practice than will double-blind trials. Moreover, these trials should include a broad range of patients, so findings have external validity.
Studies examining effectiveness of second-generation antipsychotic drugs in the early stages of schizophrenia are scarce. 7 However, patients in the early stages of schizophrenia might well respond differently to antipsychotic drugs from those who have used them for years or even decades: dopamine-receptor sensitivity is most probably substantially different in patients who have had no previous exposure to the dopamineantagonistic effects of antipsychotic dugs than in patients who are chronically treated. 10 Moreover, trials of drugs in chronic patients often, by definition, include patients who have responded little, or been non-adherent, to previous treatments.
We undertook a pragmatic open randomised-controlled trial to compare the effectiveness of second-generation antipsychotic drugs, with that of a low dose of haloperidol, in first-episode schizophrenia.
Methods

Setting and participants
A total of 50 centres, of which 36 were university hospitals, participated; the centres were in 13 European countries and Israel. We selected the centres because of their experience of research in schizophrenia. Between Dec 23, 2002 , and Jan 14, 2006 we assessed 1047 patients for eligibility. Eligible patients were aged 18-40 years and met criteria of the diagnostic and statistical manual of mental disorders (fourth edition) for schizophrenia, schizophreniform disorder, or schizoaffective disorder; diagnoses were confirmed by the mini international neuropsychiatric interview plus (MINI plus). 11 Patients were excluded if more than 2 years had passed since the onset of positive symptoms; if any antipsychotic drug had been used for more than 2 weeks in the previous year, or for 6 weeks at any time; if patients had a known intolerance to one of the study drugs; or if patients met any of the contraindications for any of the study drugs, as mentioned in the (local) package insert texts.
Study design
The investigators informed eligible patients orally and in writing about the trial, and invited them to participate. Between 4 weeks before and 1 week after randomisation, we obtained baseline data for demographics, diagnoses, present treatment setting, psychopathology (positive and negative syndrome scale [PANSS] ), 12 severity of illness (clinical global impression [CGI] scale), 13 overall psychosocial functioning (global assessment of functioning [GAF] scale), 14 depression (Calgary depression scale for schizophrenia [CDSS] ), 15 quality of life (Manchester short assessment of quality of life scale [MANSA] ), 16 extrapyramidal symptoms (St Hans rating scale [SHRS]), 17 and sexual dysfunction (selected items from the Udvalg for Kliniske Undersøgelser [UKU]). 18 Furthermore, we physically examined all patients; recorded weight, height, and laboratory data (fasting glucose, cholesterol, HDL and LDL, fasting insulin, triglycerides, and prolactin); and obtained an electrocardiogram (ECG).
Patients were randomly assigned by a dedicated web-based online system-which was developed inhouse by the Data Management Department of the Julius Center for Health Sciences and Primary Care (version 1.2)-to daily doses of: haloperidol 1-4 mg, amisulpride 200-800 mg, olanzapine 5-20 mg, quetiapine 200-750 mg, or ziprasidone 40-160 mg. The maximum dose of haloperidol was set at 4 mg per day, since studies have suggested that patients with first-episode schizophrenia respond to low doses of antipsychotic drugs. 19, 20 Furthermore, higher doses do not increase the antipsychotic effect of haloperidol, but do increase the risk of side-effects, especially in patients with first-episode schizophrenia. [21] [22] [23] [24] [25] [26] All study drugs were given orally, within the above dose ranges, at the treating psychiatrist's discretion. The use of mood stabilisers, benzodiazepines, antidepressants, and anticholinergic drugs was allowed, and documented. Since some study drugs were not registered in all participating countries, we used a minimisation procedure to prevent unequal group sizes at the end of the trial-ie, treatment assignment of new patients depended on the distribution of participants over the treatment groups. 27 Randomisation to ziprasidone was blocked between December, 2003, and October, 2004, because the minimisation procedure used during randomisation assigned ziprasidone to too many patients, in the few countries where ziprasidone was available. Patients and their treating psychiatrists were unmasked for the assigned treatment, since this reflected routine clinical practice, increasing the trial's external validity; it also improved the trial's acceptability for patients and psychiatrists, leading to a more representative group of patients, which further increased the trial's external validity.
All participants-or their legal representativesprovided written informed consent. The trial complied with the Declaration of Helsinki, and was approved by the ethics committees of the participating centres. The Julius Centre for Health Sciences and Primary Care monitored the trial according to Good Clinical Practice and International Conference on Harmonisation guidelines.
Procedures
Before the start of the trial, site coordinators were trained to use the MINI plus and to assess outcomes-eg, video tapes were used to train assessments of the PANSS. The site coordinators could delegate assessments to competent co-investigators-eg, a psychiatrist (including a trainee in psychiatry), research nurse, or psychologist. The primary outcome was all-cause discontinuation of haloperidol, compared with discontinuation of the various second-generation antipsychotic drugs. Treatment discontinuation was defined as: (1) the use of a dose below the predefined range including complete discontinuation; 
(Continues on next page) better adherence). 28 The safety and tolerability outcomes were admission to psychiatric hospital, serious adverse events, SHRS, selected items of the UKU, weight, laboratory data, ECG, and use of concomitant drugs. Data was collected at 0·5, 1, 1·5, 2, 3, 6, 9, and 12 months for one or more of the efficacy, safety, and tolerability outcomes. In practice, more than 90% of the PANSS and CGI ratings were completed by the investigator who assessed treatment discontinuation.
Statistical analysis
We assumed a treatment discontinuation rate, at 12-month follow-up, of 70% in patients receiving haloperidol, and 40% in patients receiving second-generation antipsychotic drugs (hazard ratio [HR] 0·42). We needed 45 patients per treatment group, on the basis of a two-tailed test with α=5% and 1-β=80%. However, we suspected that the discontinuation rate of haloperidol might be smaller than was inferred from previous studies, since we intended to use low doses of haloperidol. Therefore we planned to enrol 100 patients per group-ie, 500 patients in total.
Analysis was by intention to treat. Given the definition of treatment discontinuation, patients were not at risk for the outcome within the first 2 weeks after randomisation. Therefore, these 2 weeks were not considered for analysis of treatment discontinuation. 
We used Kaplan-Meier curves to estimate the probability of treatment discontinuation at 12 months. Cox proportional-hazards regression analysis was used to estimate differences of discontinuation probabilities between haloperidol and the four second-generation antipsychotic drugs, adjusted for country, since in some countries not all study drugs were included in the randomisation process. Differences were expressed in HRs, with corresponding 95% CIs. Countries with 15 or fewer patients were clustered to prevent unstable estimates.
We used data obtained before treatment discontinuation for analysis of secondary outcomes. We compared continuous efficacy outcomes, that were repeatedly measured after baseline, between treatment groups, with longitudinal multilevel linear mixed-effects regression models. 29 We studied whether the association of the continuous variable time from baseline with the secondary outcomes was linear, and we transformed the variable when appropriate. The multilevel model included random effects for the intercepts of the regression model and time coefficient of individual patients. The models HR=hazard ratio. *Proportion of patients who have received the maximum or even a higher dose for at least 1 day. †The percentages are Kaplan-Meier estimates of treatment discontinuation within 12 months. ‡Kaplan-Meier estimates. Months at risk for treatment discontinuation, excluding the first 14 days after randomisation. For amisulpride and olanzapine no upper limit for the CI could be estimated because the upper limit is above the maximum follow-up time. The 95% CI includes the true population 25th percentile with probability 0·95. §Cox proportional-hazards regression models, with adjustments for country. included fixed effects for treatment group, baseline score, and country. We tested the interaction between treatment group and time, and included it in the model when statistically significant. Comparisons between treatment groups of continuous safety and tolerability outcomes were assessed with linear regression, accounting for the time at risk and adjusting for country. Dichotomous safety and tolerability outcomes were studied with Poisson regression analysis, accounting for the time at risk for an adverse event and adjusting for country. We analysed weight change in a manner similar to that used for the efficacy outcomes. Subgroup analyses devised post-hoc were: sex, suicidality at baseline (suicidal vs non-suicidal patients), and substance dependence or abuse at baseline (patients with substance dependence or abuse vs patients without substance dependence or abuse).
We analysed all secondary outcomes with S-Plus (version 6.1), and the other data with SPSS (12.0). All statistical tests were two-sided. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN68736636.
Role of the funding sources
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. Figure 1 shows the trial profile. 498 patients were randomly assigned to five treatment groups (figure 1). During follow-up, some enrolled patients appeared not to be eligible: 11 patients (four on haloperidol, two on olanzapine, two on quetiapine, and three on ziprasidone) had another cause for the symptoms than schizophrenia, another patient on quetiapine had positive symptoms exceeding 2 years before randomisation, and two patients on amisulpride had used antipsychotic drugs for more than 2 weeks in the previous year. These patients, and those who did not take any dose of the assigned study medication, were included in the analysis. Baseline characteristics of randomised patients were much the same between the groups (table 1). Table 2 shows the mean antipsychotic doses given every day, and the proportions of patients who discontinued treatment for any cause.
Results
Treatment discontinuation for any cause differed between treatment groups (p<0·0001; table 2), and was substantially lower in patients on all of the second-generation antipsychotic drugs than in those taking haloperidol (figure 2). Additionally, treatment discontinuation because of insufficient efficacy differed between treatment groups (p<0·0001; table 2), with the risk of discontinuation lower in patients on second-generation antipsychotic drugs than in those on haloperidol (figure 2), although the difference between haloperidol and quetiapine was not significant (table 2) . Treatment discontinuation because of side-effects also differed between treatment groups (p=0·023; table 2), which was mostly attributable to better tolerability of olanzapine and quetiapine than that of haloperidol (figure 2). Discontinuation of treatment for non-adherence did not differ significantly between treatment groups (p=0·241; table 2 and figure 2). GAF=global assessment of functioning. The lowest curve for GAF scores consists of the haloperidol and quetiapine curves, which are almost identical. Figure 3 shows the decrease of the total scores for psychopathology (PANSS) and severity of illness (CGI), and the increase of the overall functioning scores (GAF) of the five treatment groups during the 12 months follow-up. The differences between the treatment groups and the interaction between treatment and time were not significant for the PANSS (p=0·70 and p=0·15, respectively), but were significant for the CGI scale (p=0·0006 and p=0·003) and the GAF scale (p=0·006 and p=0·016). We recorded no significant differences between treatment effects for the depression score (CDSS), quality-of-life score (MANSA), and adherence with antipsychotic drugs (data not shown). Table 3 shows the mean scores for the efficacy outcomes at 12 months. Change from baseline
Per month in study Data are n/N (%) or mean (SE), unless otherwise indicated. SHRS=St Hans rating scale. UKU=udvalg for kliniske undersøgelser. Denominators fluctuate because of incomplete data. p values are based on tests that compare all treatment groups (four degrees of freedom), accounting for time at risk and adjusting for country. *p values could not be estimated because of low numbers of events. †Percentages are based on the number of patients with at least one follow-up assessment (SHRS and UKU: 1, 3, 6, 9, 12 months)-patients scored positive on at least one evaluation. The analyses on extrapyramidal symptoms were also adjusted for the use of anticholinergic drugs before extrapyramidal symptoms. UKU: cases scored moderate/severe on severity of sexual dysfunction. ‡Percentages and change scores are based on the patients with at least one follow-up assessment (3, 6, 9, 12 months). The maximum weight measured during follow-up was analysed for overweight and weight gain; mean weight change scores were estimated at 12 months. §Percentages are based on the number of patients with at least one assessment after baseline (6 and 12 months). The highest lab value measured during follow-up and the corresponding blood collection date were selected for the analyses. For HDL we selected the lowest lab value. ¶Hyperprolactinaemia: men >0·38 U/L; women >0·53 U/L (men >18 ng/mL; women >25 ng/mL; to convert values in ng/mL to U/L we arbitrarily used a conversion factor of 0·0212). 20 (table 4) . Subgroup analyses for sex, suicidality, and substance abuse did not show statistically significant differences on all-cause treatment discontinuation between patients on haloperidol and those taking second-generation antipsychotic drugs (data not shown). Our results did not change after exclusion of patients who did not take the assigned antipsychotic drug, or did not meet the inclusion criteria (data not shown).
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Discussion
Our study has shown that in patients with first-episode schizophrenia and schizophreniform disorder, treatment discontinuation over 12 months was significantly greater in patients given a low dose of haloperidol than in those assigned to treatment with second-generation antipsychotic drugs, with the lowest discontinuation with olanzapine. However, symptomatic improvement (measured by PANSS) and rates of admission to hospital did not differ significantly between groups. Global improvement as measured with the CGI or GAF scales differed between treatments, with most improvement recorded with amisulpride and least with quetiapine and haloperidol.
Side-effects varied-signs of parkinsonism were more frequent with haloperidol than with second-generation antipsychotic drugs, whereas weight change was most pronounced in patients on olanzapine, and lowest in those on haloperidol and ziprasidone. Patients on haloperidol and amisulpride were most likely to be prescribed anticholinergic drugs, and patients on olanzapine were prescribed antidepressants most often. We noted few patients with dystonia, even in the haloperidol group, suggesting that the low dose used in this study is well tolerated in this respect. Overall, the side-effects that we recorded are generally consistent with those from other studies, although the findings on antidepressant prescription were different from those of a previous study, in which olanzapine decreased depressive symptoms in patients with schizophrenia. 19 Schooler and colleagues 20 undertook a large (n=555), double-blind, randomised trial comparing the effects of risperidone (mean dose 3·3 mg)-a second-generation antipsychotic drug-with a low dose of haloperidol (2·9 mg), in patients with recent onset schizophrenia, over 1 year. The primary outcome was the number of relapses, but discontinuation rates were also reported, and did not significantly differ between the two groupsaround 36·5% for haloperidol, and 42% for risperidone. Patients with drug abuse and concomitant drugs were excluded, and previous antipsychotic treatment was allowed for up to 12 weeks. In another double-blind study of 263 patients with first-episode schizophrenia, 30 haloperidol (mean dose 4·8 mg) was compared with olanzapine (10·2 mg) over a 2-year follow-up. This sample was predominantly male (82%), and previous treatment was kept to a maximum of 16 weeks. Patients who abused drugs were excluded. Estimated discontinuation rates at 1 year (data extrapolated by us) were much higher than in our study-about 75% for the haloperidol group and around 65% for olanzapine, with a significantly larger group continuing treatment with olanzapine than with haloperidol at 2 years. 30 Although the discontinuation rate for haloperidol in that double-blind study was similar to that in our trial, the rate with olanzapine was substantially higher than it was in our sample. A 1-year double-blind study comparing effectiveness, defined as completion rates on the assigned drug, between olanzapine, quetiapine, and risperidone (n=400), in patients with recent onset schizophrenia reported low completion rates, of Time to treatment discontinuation for any cause in patients assigned to haloperidol at sites at which the coordinator thought that haloperidol was the worst option, versus sites at which the coordinator believed that it was not about 30%. 31 Discontinuation rates did not differ between the drugs tested.
In a double-blind study, the CATIE trial compared the effectiveness of second-generation antipsychotic drugs with that of the low-potency first-generation drug perphenazine:
8 1493 patients with chronic schizophrenia were randomly assigned to olanzapine, quetiapine, risperidone, ziprasidone, and perphenazine. Consistent with our results, when insufficient efficacy was the reason for discontinuation, time to discontinuation was longer in the olanzapine group than in the perphenazine and quetiapine groups. However, we noted that olanzapine also showed a longer time to discontinuation than did ziprasidone, which was different from what was reported in CATIE. Furthermore, discontinuation rates with second-generation antipsychotic drugs were substantially lower in our study.
Just as discontinuation rates were lower in our study than in other trials, symptomatic improvement was more pronounced than in other long-term studies of first-episode schizophrenia. Although symptom severity at baseline was comparable with that in other studies 20, 30, 31 (ie, PANSS scores of around 75-90), we recorded a symptom reduction of around 35 points, whereas in most other studies it varied from 18 to 21. The minimum score on the PANSS is 30, meaning that the symptom reduction in this study was more than 60%, which is regarded as a clinically meaningful response. 32 By contrast, other studies recorded symptom reductions of 40%. 20, 31 At 12 months of treatment, mean global functioning was good: borderline mentally ill to mildly ill on the severity of illness scale (CGI), with mean overall functioning (GAF) scores of more than 65 (ie, moderate to mild symptoms, or moderate to some difficulty in social, occupational, or educational functioning).
How can we account for the differences between our results and those of previous studies? Patients with first-episode schizophrenia are likely to do better than are those with chronic schizophrenia-partly because they might be more sensitive to drugs, and partly because they are a much more heterogeneous group. Notably, two-fifths of our patients met the diagnostic criteria for schizophreniform disorder, but not for schizophrenia or schizoaffective disorder, so might have been especially likely to respond to treatment. Our trial was an open trial, in which patients may respond better to treatment than in double-blind trials. We did not include a placebo group: indeed, long-term placebo studies are very rare in schizophrenia. However, a study that followed up chronic patients for at least 1 year reported symptomatic worsening of around 30% in patients on placebo, 33 increasing the likelihood that the improvement reported in our patients was clinically meaningful. We used broad inclusion criteria, aiming to make our findings as externally valid as possible. 40% of our patients were women, a proportion similar to that in the population with schizophrenia. 34 We did not use the same selection of drugs as did other trials. Notably, we used the high-potency first-generation drug haloperidol, whereas CATIE used perphenazinewhich, like chlorpromazine, is a low-potency drug. Low-potency first-generation antipsychotic drugs, especially in low doses, might not be more likely than second-generation drugs to cause extrapyramidal symptoms. 4 Patients are not treated in a vacuum, and systems of health care and social care differ between the USA and Europe. The extent to which this might affect outcomes remains a matter of speculation.
How do we explain the discrepancy between PANSS scores and readmission rates, on the one hand, and discontinuation rates, on the other? Patients were not significantly more likely to be non-adherent to haloperidol than to be non-adherent to other drugs. Moreover, the discontinuation rates of haloperidol were much closer to those of risperidone and olanzapine in two earlier double-blind long-term studies. 19, 20 We therefore wondered whether expectations of psychiatrists could have led to haloperidol being discontinued more often, in our open study. Such an occurence would have important implications for the interpretation of trials in psychiatry, since even in double-blind studies, blindness can often not be fully maintained, because different drugs tend to have different side-effects-so the results of effectiveness trials could reflect provider bias.
We assessed provider expectations at the end of the study, but before any of the analyses were undertaken. We obtained data from 32 (64%) of the 50 site coordinators. 11 (34%) site coordinators expected haloperidol to lead to the worst outcome, and 21 (66%) of them thought that it be no worse than the second-generation drugs. We tested whether discontinuation rates for haloperidol were different for patients from the sites at which haloperidol was expected to do worse than in the other sites, and noted a non-significant difference (HR 1·39 [95% CI 0·28-6·97], p=0·69; figure 4).
We conclude that although the high continuation rates for several of the second-generation antipsychotic drugs suggest that clinically meaningful long-term antipsychotic treatment is achievable in the first-episode of schizophrenia, it cannot be concluded that second-generation antipsychotic drugs are more efficacious than is haloperidol in the treatment of these patients.
strategies and measuring outcomes important to patients hinders efforts of clinicians and patients to improve the safety and efficacy of treatments for type 2 diabetes. 
Pharmacotherapy of first-episode schizophrenia
See Articles page 1085 For the past 15 years, atypical antipsychotic drugs have become the predominant drugs for the treatment of schizophrenia. In today's Lancet, René Kahn and colleagues 1 present the results of a large (nearly 500 patients), 12-month randomised study of four of these newer medications and one older drug, haloperidol, in the treatment of first-episode schizophrenia or schizophreniform disorder. They unexpectedly conclude that the atypical antipsychotics could not be proven superior to the older drug, in part because the unblinded study design precluded unbiased assessment of time to all-cause treatment discontinuation, the primary outcome.
When this study began in 2002, enthusiasm for the new drugs was at a peak, and conscientious doctors, believing their patients had been assigned to an older, inferior drug would have felt urgency, even in the context of a clinical trial, to switch their patients to newer, purportedly superior, treatments. The two measures most likely to be influenced by the subjective impressions of clinicians who know what drug they are using-the decision to change drugs and the global assessment of function rating-showed the greatest benefit for the newer drugs. By contrast, there was no benefit for any of the atypical drugs on psychometrically more sophisticated measures of symptom severity and quality of life based on responses of patients to extensive sets of questions or on rehospitalisation. Although use of an open treatment was meant to facilitate enrolment of a widely representative sample of patients and evaluation of treatments as delivered in day-to-day practice, it might also have introduced what the authors candidly refer to as provider bias to the assessment of the primary outcome measure. Kahn and colleagues also note that the size of differences between responses to atypical and conventional antipsychotics are greater in their unblinded study than in studies that sought to maintain blinded treatment in both patients and providers.
Beyond these unexpected results, the study also addresses some of the subtler questions surrounding medical research with commercial sponsors. Following contemporary standards, the authors clearly disclose that the manufacturers of three of the patented drugs funded the study and indicate that they had full control of the analysis and presentation of the data as well as the study design. They also seem to have dealt with an organisational intermediary, implying limited direct contact with the sponsors, an important advantage. Furthermore, during peer review, the authors showed a further level of conduct, specifying that the industry sponsors had seen the study before agreeing to become a sponsor, and that the sponsors had not suggested any change to the protocol". This procedure goes further than the current standard of reporting, especially in that the investigators vouch for the fact that the sponsors made no input to the study design (although presumably they could have decided not to fund it if they disapproved, and the protocol could have been designed specifically to appeal to commercial sponsors). Perhaps a description of the involvement of sponsors in designing study protocols, or, as in this case, the laudable lack thereof, should become a standard for the publication of industry-sponsored trials.
A third important feature of this study is that it represents an instance in which the peer-review process successfully drew attention to methodological limitations that were noted in the original submission. The sometimes extensive deliberations between reviewers, editors, and authors are rarely made public, primarily to protect the anonymity of reviewers, but the occasional disclosure of such deliberations could be reassuring to many concerned with the integrity of published research.
Several large, independent government-led trials have found little or no advantage for atypical antipsychotics over older drugs in the treatment of chronic schizophrenia, especially when compared with intermediate-potency drugs like perphenazine or high-potency drugs used in low doses or with prophylactic anticholinergics. [2] [3] [4] [5] A reduced risk of neurological side-effects with new drugs, at least in comparison with haloperidol, is evident in the present study, 1 but no such differences were found in a comparison with perphenazine, a drug with less risk, 3 and a recent review suggests that even the low risk of tardive dyskinesia with atypical antipsychotics, the most serious neurological side-effect, is not, by itself, likely to justify the greater expense of these drugs. 6 Such benefits may also be offset by increased weight gain and metabolic risk. However, in this study of patients with a first-episode of schizophrenia, differences between treatments in weight gain were not significant.
There clearly seems to be much less, if any, ground for enthusiasm about these costly drugs now than in 2002, precisely because of the findings of large, independent double-blind trials. The revised Texas Medication Algorithm Project recently found no reason to prefer atypical antipsychotics over conventional drugs in chronic schizophrenia, and although it favoured the use of atypical drugs in first-episode treatment, there seems to have been divided opinion over this recommendation. 7 Whether use of atypical antipsychotics in either chronic or first-episode schizophrenia should be limited to situations in which they are specifically indicated (eg, in the presence of tardive dyskinesia, akithesia, or pseudoparkinsonism) is a question that must now be faced head-on. Addressing this question poses a major challenge to both cost-effectiveness assessment and to mental-health policy making.
